抗体药-话题@MedSci

#抗体药#

67篇内容 | 922人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1957653, encodeId=f93e195e65313, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=JAMA Oncol：抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤, objectType=article, longId=727924, objectId=0dbbe2792428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dbbe2792428, replyNumber=0, likeNumber=46, createdTime=2022-06-03, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dbbe2792428, moduleTitle=JAMA Oncol：抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dbbe2792428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957650, encodeId=9eb0195e6505c, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线, objectType=article, longId=293894, objectId=b4132938940e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4132938940e, replyNumber=0, likeNumber=40, createdTime=2022-02-01, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4132938940e, moduleTitle=Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4132938940e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957654, encodeId=98de195e65466, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展, objectType=article, longId=732978, objectId=3ce1e32978e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ce1e32978e9, replyNumber=0, likeNumber=37, createdTime=2023-06-20, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ce1e32978e9, moduleTitle=百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ce1e32978e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957652, encodeId=5e78195e65216, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔, objectType=article, longId=295514, objectId=81472955144d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81472955144d, replyNumber=0, likeNumber=35, createdTime=2022-05-19, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81472955144d, moduleTitle=2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81472955144d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957649, encodeId=6736195e64990, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤, objectType=article, longId=293438, objectId=5c862934382f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c862934382f, replyNumber=0, likeNumber=37, createdTime=2022-12-06, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c862934382f, moduleTitle=Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c862934382f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957651, encodeId=7070195e651c5, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=Nature Med：GD2与CD47抗体药联用显示广谱抗癌潜能, objectType=article, longId=294505, objectId=33c729450500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c729450500, replyNumber=0, likeNumber=43, createdTime=2022-07-03, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c729450500, moduleTitle=Nature Med：GD2与CD47抗体药联用显示广谱抗癌潜能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33c729450500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎, objectType=article, longId=220524, objectId=62c1220524a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c1220524a2, replyNumber=0, likeNumber=39, createdTime=2022-02-03, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c1220524a2, moduleTitle=Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62c1220524a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957645, encodeId=9aa7195e64575, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议, objectType=article, longId=213183, objectId=364e2131837c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=364e2131837c, replyNumber=0, likeNumber=44, createdTime=2021-07-25, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=364e2131837c, moduleTitle=LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=364e2131837c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957648, encodeId=6a75195e64806, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=37, createdTime=2022-07-23, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957646, encodeId=6642195e64658, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=安进以25亿美元收购Teneobio公司，夯实新型抗体药物领导地位, objectType=article, longId=214968, objectId=29c6214968c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29c6214968c5, replyNumber=0, likeNumber=37, createdTime=2022-06-25, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29c6214968c5, moduleTitle=安进以25亿美元收购Teneobio公司，夯实新型抗体药物领导地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29c6214968c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957644, encodeId=e56f195e6445e, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=GSK抗体药物otilimab治疗COVID-19，已在老年患者中显示潜力！, objectType=article, longId=207672, objectId=49f720e67299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49f720e67299, replyNumber=0, likeNumber=35, createdTime=2021-05-04, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49f720e67299, moduleTitle=GSK抗体药物otilimab治疗COVID-19，已在老年患者中显示潜力！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49f720e67299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957637, encodeId=646a195e637a5, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, objectType=article, longId=196920, objectId=36881969209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36881969209a, replyNumber=0, likeNumber=42, createdTime=2021-04-25, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36881969209a, moduleTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36881969209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957635, encodeId=956d195e635ab, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好, objectType=article, longId=195863, objectId=9d4319586365, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d4319586365, replyNumber=0, likeNumber=35, createdTime=2021-04-24, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d4319586365, moduleTitle=抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d4319586365)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957639, encodeId=0dad195e639a3, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, objectType=article, longId=197261, objectId=e32219e26199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e32219e26199, replyNumber=0, likeNumber=50, createdTime=2021-06-08, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e32219e26199, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e32219e26199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957631, encodeId=feb7195e6313c, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=31, createdTime=2021-02-16, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, objectType=article, longId=198901, objectId=876c19890119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=876c19890119, replyNumber=0, likeNumber=44, createdTime=2021-07-11, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=876c19890119, moduleTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=876c19890119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957642, encodeId=df4d195e64230, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, objectType=article, longId=199921, objectId=e4ad199921fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ad199921fd, replyNumber=0, likeNumber=45, createdTime=2021-03-21, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ad199921fd, moduleTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ad199921fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957643, encodeId=982b195e6437f, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=泰诺麦博与西门子合作打造抗体药物数字化工厂, objectType=article, longId=202880, objectId=58532028804f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58532028804f, replyNumber=0, likeNumber=33, createdTime=2021-04-28, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58532028804f, moduleTitle=泰诺麦博与西门子合作打造抗体药物数字化工厂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58532028804f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=36, createdTime=2020-12-11, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957628, encodeId=82b4195e62808, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, objectTitle=Sci Adv：程柯团队带来抗体药物靶向受损心脏新方法, objectType=article, longId=187650, objectId=405818e650e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405818e650e0, replyNumber=0, likeNumber=31, createdTime=2020-10-18, rootId=0, userName=12498e5fm12(暂无昵称), userId=793a2500200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405818e650e0, moduleTitle=Sci Adv：程柯团队带来抗体药物靶向受损心脏新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=405818e650e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗体药

2020-05-29

柳叶一刀 (审核中...)

前往app查看评论内容

#抗体药#

JAMA Oncol：抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤

2022-06-03

柳叶一刀 (审核中...)

前往app查看评论内容

#抗体药#

Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线

2022-02-01

柳叶一刀 (审核中...)

前往app查看评论内容

#抗体药#

百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展

2023-06-20

柳叶一刀 (审核中...)

前往app查看评论内容

#抗体药#

2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔

2022-05-19

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤

2022-12-06

柳叶一刀 (审核中...)

前往app查看评论内容

#抗体药#

Nature Med：GD2与CD47抗体药联用显示广谱抗癌潜能

2022-07-03

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎

2022-02-03

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议

2021-07-25

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2022-07-23

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

安进以25亿美元收购Teneobio公司，夯实新型抗体药物领导地位

2022-06-25

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

GSK抗体药物otilimab治疗COVID-19，已在老年患者中显示潜力！

2021-05-04

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌

2021-04-25

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好

2021-04-24

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查

2021-06-08

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2021-02-16

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤

2021-07-11

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究

2021-03-21

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

泰诺麦博与西门子合作打造抗体药物数字化工厂

2021-04-28

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2020-12-11

12498e5fm12(暂无昵称) (审核中...)

前往app查看评论内容

#抗体药#

Sci Adv：程柯团队带来抗体药物靶向受损心脏新方法

2020-10-18

科室
- - 订阅+
  - 更多科室
工具
服务